The Synthesis
What's actually happening across the UK research-peptide industry — told by the people in it, checked against what's actually true.
Most of what gets written about research peptides online falls into one of two camps: it's trying to sell you something, or it's so vague and generic it could've been written about any industry. The Synthesis is trying to be neither. We cover three things, each for a different reason.
Long-form conversations with the people actually running peptide businesses — founders, operators, suppliers. What's working, what's broken, what they'd do differently if they started again. Issue 01 is live now, below.
A page per compound, covering what the research actually says — not dosing advice, not administration guidance, just a clear picture of what's been studied and where the evidence actually stands. Where it adds something real, we'll bring in perspective from researchers and clinicians alongside what suppliers themselves say about a compound, so you're not just hearing one side of it.
Honest looks at suppliers across the UK market — not only the ones who've approached us as partners. Some companies do this well. Some don't. We'll say which is which, with reasons you can actually check, because a comparison that only ever says nice things isn't a comparison.
Partner features are always labelled, always disclosed, and never the reason a company gets covered in the first place. Want to be considered for an upcoming issue?